University of Porto, Portugal
Bruno Sarmento is a Research Scientist and Assistant Professor associated to the Department of Pharmaceutical Technology of Faculty of Pharmacy of University of Porto and Department of Pharmaceutical Sciences of Instituto Superior de Ciências da Saúde- Norte. Bruno Sarmento has completed his Ph.D at the age of 28 years from University of Porto in the area of oral absorption of proteins encapsulated into nanoparticulate systems, throughout he was able to work in some research laboratories in Europe and Canada during the last few years acquiring a deep experience on the field of nanoencapsulation as well as on the protein structure analysis cell culture and animal in vivo studies.His actual interests of research are focused on non-invasive delivery of biopharmaceuticals by means of colloidal targets, development of new drug delivery systems using polymeric nanoparticles and controlling delivery of drugs across biological barriers, namely gastrointestinal and pulmonary routes. He has published more than 50 papers in reputed journals and book chapters and serving as an editorial board member of international journals. He is also an active member of several international associations (AAPS, CRS, EUFEPS, EFSD, FIP, BRG) and member of the organizer committee of scientific meetings. Further is work as research scientist in various research projects and Professor he is also supervisor of many PhD, postdoctoral and master students.
Insulin has usually been administered subcutaneously in the treatment of diabetes mellitus. Oral delivery of insulin is expected to be an alternative route but has some limitations, including low HK,the luminal cavity, and poor permeability across intestinal epithelium because of its high molecular weight and lack of lipophilicity. Solid lipid nanoparticles (SLN) show several advantages as drug delivery systems, such as good tolerability, biodegradation, and the possibility of large industrial scale production. Enhancing mucoadhesion properties of nanoparticles, namely by using chitosan coating has been a successful strategy used to promote the contact of carriers with the intestinal epithelium, thus increasing the therapeutic proteins concentration at the site of absorption. In this presentation, it will be present the recent advances of our research group on the developing of a new nanoparticulate carrier intended for the oral insulin administration, composed of a lipid core aimed to protect and to control the release of insulin and coated by the mucoadhesive chitosan to improve insulin absorption. In vitro permeation experiments in Caco-2 and Caco-2/HT20 cell cultures demonstrated the ability of insulin to cross through the intestinal mucosa, mainly when encapsulated into chitosan-coated SLN. Insulin-loaded SLN decreased glycemia in diabetic animal model compared oral insulin solution, and the hypoglycemic effect was higher when SLN are further coated with chitosan. Chitosan coating was found to improve the stability and intestinal absorption properties of SLN containing insulin, which may contribute for the development of an optimized oral insulin formulation.